Evidence map›Paper›PMID 25302088›Full record

ArticleThe Journal of clinical and aesthetic dermatology2014

Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.

James Q Del Rosso, Leon Kircik, Gary Goldenberg, Berman Brian

Abstract read
PubMed Full text at PMC
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Cancer Immunoprevention: Current Status and Future Directions.Archivum immunologiae et therapiae experimentalis · 2021
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James Q Del RossoDr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa.
Leon KircikDr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa.
Gary GoldenbergDr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa.
Berman BrianDr. Del Rosso is an investigator, consultant, and speaker for LEO Pharma Inc. and a consultant and speaker for Valeant Pharmaceuticals and Ferndale Laboratories. Dr. Kircik is an investigator, consultant, and speaker for LEO Pharma Inc. and has served as an investigator, consultant, and/or speaker for Dusa, Ferndale, and Valeant. Dr. Goldenberg is a speaker and consultant for and provides research support for LEO Pharma Inc., Valeant, and PharmaDerm. Dr. Berman served on advisory boards of Graceway Pharmaceuticals, LEO Pharma Inc., Medicis, and PharmaDerm; as a consultant for Graceway Pharmaceuticals, Medicis, Dusa, Valeant, and LEO Pharma Inc.; as a speaker for LEO Pharma Inc., Medicis, PharmaDerm, Valeant, and Dusa; and as an investigator for LEO Pharma, Medicis, and Dusa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID25302088
PMCPMC4187997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.